Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Single-arm, Open-label, Multicenter Study of the Safety and Efficacy of Dirloctocogene Samoparvovec (SPK 8011, Adeno-associated Viral Vector With B-domain Deleted Human Factor VIII Gene) in Adults With Severe or Moderately Severe Hemophilia A

NCT06297486 is registered in ClinicalTrials.gov with Spark Therapeutics, Inc. as lead sponsor.

NCT NCT06297486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06297486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Single-arm, Open-label, Multicenter Study of the Safety and Efficacy of Dirloctocogene Samoparvovec (SPK 8011, Adeno-associated Viral Vector With B-domain Deleted Human Factor VIII Gene) in Adults With Severe or Moderately Severe Hemophilia A
Lead sponsor
Spark Therapeutics, Inc.
Phase
Phase 3
Overall status
Withdrawn
Start date
March 13, 2024
Completion date
September 4, 2035
Enrollment
0 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a